The 3D cell culture industry is poised for substantial growth from 2025 to 2035, driven by advancements in biotechnology and an increasing emphasis on more accurate and relevant in vitro models.
The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback